Emerging drugs to replace current leaders in first-line therapy for breast cancer

Expert Opinion on Emerging Drugs

Volumn 11, Issue 3, 2006, Pages 489-501

  Cox, Michael C ^a   Dan, Tu D ^a   Swain, Sandra M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Adjuvant therapy; Bevacizumab; Ixabepilone; Lapatinib; Pertuzumab

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CIMETIDINE; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPOTHILONE DERIVATIVE; EVEROLIMUS; IXABEPILONE; LAPATINIB; LETROZOLE; LONAFARNIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PACLITAXEL; PERTUZUMAB; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RANITIDINE; SUNITINIB; TAXANE DERIVATIVE; TEMSIROLIMUS; TIPIFARNIB; TRASTUZUMAB; WARFARIN;

ARTHRALGIA; ASTHENIA; BRAIN DISEASE; BREAST CANCER; CANCER STAGING; CLINICAL TRIAL; DIARRHEA; DRUG HALF LIFE; DRUG MECHANISM; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERTENSION; META ANALYSIS; MUCOSA INFLAMMATION; MYALGIA; NEPHROTIC SYNDROME; NEUROPATHY; PROTEINURIA; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; TECHNOLOGY, PHARMACEUTICAL;

EID: 33748643613     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.11.3.489     Document Type: Review

References (103)

1. JEMAL A, SIEGEL R, WARD E et al.: Cancer Statistics, 2006. CA Cancer J. Clin. (2006) 56(2):106-130.
2. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide, [program]. version 2.0 version. Lyon: IARCPress (2004).
3. MCPHERSON K, STEEL CM, DIXON JM: ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ (2000) 321(7261):624-628.
4. RIES L, EISNER M, KOSARY C et al.: SEER Cancer Statistics Review, 1975 - 2002. National Cancer Institute, Bethesda, MD, USA (2005).
5. MICHAELSON JS, SILVERSTEIN M, WYATT J et al.: Predicting the survival of patients with breast carcinoma using tumor size. Cancer (2002) 95(4):713-723.
6. EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 365(9472):1687-1717.
7. BONADONNA G, MOLITERNI A, ZAMBETTI M et al.: 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ (2005) 330(7485):217.
8. BONADONNA G, VALAGUSSA P, MOLITERNI A, ZAMBETTI M, BRAMBILLA C: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer - the results of 20 years of follow-up. N. Engl. J. Med. (1995) 332(14):901-906.
9. HOLMES FA, WALTERS RS, THERIAULT RL et al.: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J. Natl. Cancer Inst. (1991) 83(24):1797-1805.
10. NABHOLTZ JM, GLIGOROV J: The role of taxanes in the treatment of breast cancer. Expert Opin. Pharmacother. (2005) 6(7):1073-1094.
11. HENDERSON IC, BERRY DA, DEMETRI GD et al.: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J. Clin. Oncol. (2003) 21(6):976-983.
12. MAMOUNAS EP, BRYANT J, LEMBERSKY BC et al.: Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J. Clin. Oncol. (2005) 23(16):3686-3696.
13. CITRON M, BERRY DA, CIRRINCIONE C et al.: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer And Leukemia Group B Trial 9741. J. Clin. Oncol. (2003) 21(8):1431-1439.
14. HUDIS C, CITRON M, BERRY D et al.: Five year follow-up of INT C9741: dose-dense (DD) chemotherapy (CRx) is safe and effective. San Antonio Breast Cancer Symposium 2005. San Antonio, TX, USA (2005):abstract 41.
15. MARTIN M, PIENKOWSKI T, MACKEY J et al.: Adjuvant docetaxel for node-positive breast cancer. N. Engl. J. Med. (2005) 352(22):2302-2313.
16. SLAMON DJ, CLARK GM, WONG SG et al.: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 235(4785):177-182.
17. SLAMON DJ, GODOLPHIN W, JONES LA et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 244:707-712.
18. PEGRAM MD, KONECNY GE, O'CALLAGHAN C et al.: Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J. Natl. Cancer Inst. (2004) 96(10):739-749.
19. NAGATA Y, LAN KH, ZHOU X et al.: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell (2004) 6(2):117-127.
20. COBLEIGH MA, VOGEL CL, TRIPATHY D et al.: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. (1999) 17(9):2639-2648.
21. SLAMON DJ, LEYLAND-JONES B, SHAK S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. (2001) 344(11):783-792.
22. ROMOND EH, PEREZ EA, BRYANT J et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. (2005) 353(16):1673-1684.
23. NABHOLTZ JM, REESE DM, LINDSAY MA, RIVA A: HER2-positive breast cancer: update on Breast Cancer International Research Group trials. Clin. Breast Cancer (2002) 3(Suppl. 2):S75-S79.
24. SLAMON DJ, EIERMANN W, ROBERT NJ et al.: Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin, and trastuzumab (TCH) in HER2 positive early breast cancer patients; BCIRG 006 study. San Antonio Breast Cancer Symposium 2005. San Antonio, TX, USA (2005):abstract 1.
25. PICCART-GEBHART MJ, PROCTER M, LEYLAND-JONES B et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. (2005) 353(16):1659-1672.
26. TEN TIJE AJ, VERWEIJ J, LOOS WJ, SPARREBOOM A: Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin. Pharmacokinet. (2003) 42(7):665-685.
27. MIELKE S, SPARREBOOM A, STEINBERG SM et al.: Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin. Cancer Res. (2005) 11(13):4843-4850.
28. SCRIPTURE CD, SZEBENI J, LOOS WJ, FIGG WD, SPARREBOOM A: Comparative in vitro properties and clinical pharmacokinetics of paclitaxel following the administration of taxol(R) and paxene(R). Cancer Biol. Ther. (2005) 4(5):555-560.
29. IBRAHIM NK, DESAI N, LEGHA S et al.: Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin. Cancer Res. (2002) 8(5):1038-1044.
30. SPARREBOOM A, SCRIPTURE CD, TRIEU V et al.: Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (taxol). Clin. Cancer Res. (2005) 11(11):4136-4143.
31. O'SHAUGHNESSY JA, TJULANDIN SA, DAVIDSON N et al.: ABI-007 (abraxane), a nanoparticle albumin-bound (nab) paclitaxel demonstrates superior efficacy versus taxol in MBC; a Phase III trial. 26th Annual San Antonio Breast Cancer Symposium 2003. San Antonio, TX, USA (2003):abstract 44.
32. BLUM J, SAVIN M, EDELMAN G et al.: Long term disease control in taxane-refractory metastatic breast cancer treated with nab paclitaxel. Proc. Am. Soc. Clin. Oncol. (2004):abstract 543.
33. LEE FY, BORZILLERI R, FAIRCHILD CR et al.: BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin. Cancer Res. (2001) 7(5):1429-1437.
34. YAMAGUCHI H, PARANAWITHANA SR, LEE MW et al.: Epothilone B analogue (BMS-247550)-mediated cytotoxicity through induction of Bax conformational change in human breast cancer cells. Cancer Res. (2002) 62(2):466-471.
35. ABRAHAM J, AGRAWAL M, BAKKE S et al.: Phase I trial and pharmacokinetic study of BMS-247550, an epothilone analog, administered intravenously on a daily schedule for five days. J. Clin. Oncol. (2003) 21(9):1866-1873.
36. MANI S, MCDAID H, HAMILTON A et al.: Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin. Cancer Res. (2004) 10(4):1289-1298.
37. ZHUANG SH, AGRAWAL M, EDGERLY M et al.: A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days. Cancer (2005) 103(9):1932-1938.
38. LOW JA, WEDAM SB, LEE JJ et al.: Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J. Clin. Oncol. (2005) 23(12):2726-2734.
39. BROPHY DF, ISRAEL DS, PASTOR A et al.: Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers. Antimicrob. Agents Chemother. (2000) 44(4):978-984.
40. PINTO AG, WANG YH, CHALASANI N et al.: Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression. Clin. Pharmacol. Ther. (2005) 77(3):178-188.
41. THOMAS E, TABERNERO J, FORNIER M et al.: A Phase II study of the epothilone B analog BMS-247550 in patients (pts) with taxane-resistant metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. (2003):abstract 30.
42. ROCHE HH, CURE H, BUNNELL C et al.: A Phase II study of epothilone analog BMS-247550 in patients (pts) with metastatic breast cacner (MBC) previously treated with an anthracycline. Proc. Am. Soc. Clin. Oncol. (2003):abstract 69.
43. LEE F, CASTANEDA S, INIGO I et al.: Ixabepilone (BMS-247550) plus trastuzumab combination chemotherapy induces synergistic antitumor efficacy in HER2 dependent breast cancer and is accompanied by modulation of molecular reponse markers. Proc. Am. Soc. Clin. Oncol. (2005):abstract 561.
44. RUBIN EH, ROTHERMEL J, TESFAYE F et al.: Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors. J. Clin. Oncol. (2005) 23(36):9120-9129.
45. FOLKMAN J: Tumour angiogenesis: therapeutic implications. N. Engl. J. Med. (1971) 285:1182-1186.
46. FOLKMAN J: Clinical applications of research on angiogenesis. N. Engl. J. Med. (1995) 333(26):1757-1763.
47. NICHOLSON B, THEODORESCU D: Angiogenesis and prostate cancer tumor growth. J. Cell Biochem. (2004) 91(1):125-150.
48. HOUCK KA, LEUNG DW, ROWLAND AM, WINER J, FERRARA N: Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J. Biol. Chem. (1992) 267(36):26031-26037.
49. PARK JE, KELLER GA, FERRARA N: The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol. Biol. Cell (1993) 4(12):1317-1326.
50. BREM SS, JENSEN HM, GULLINO PM: Angiogenesis as a marker of preneoplastic lesions of the human breast. Cancer (1978) 41(1):239-244.
51. YOSHIJI H, GOMEZ DE, SHIBUYA M, THORGEIRSSON UP: Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res. (1996) 56(9):2013-2016.
52. BROWN LF, BERSE B, JACKMAN RW et al.: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum. Pathol. (1995) 26(1):86-91.
53. SPEIRS V, ATKIN SL: Production of VEGF and expression of the VEGF receptors Flt-1 and KDR in primary cultures of epithelial and stromal cells derived from breast tumours. Br. J. Cancer (1999) 80(5-6):898-903.
54. KUREBAYASHI J, OTSUKI T, KUNISUE H et al.: Expression of vascular endothelial growth factor (VEGF) family members in breast cancer. Jpn. J. Cancer Res. (1999) 90(9):977-981.
55. HOAR FJ, LIP GY, BELGORE F, STONELAKE PS: Circulating levels of VEGF-A, VEGF-D and soluble VEGF-A receptor (sFIt-1) in human breast cancer. Int. J. Biol. Markers (2004) 19(3):229-235.
56. GASPARINI G: Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist (2000) 5(Suppl. 1):37-44.
57. GASPARINI G, TOI M, BIGANZOLI E et al.: Thrombospondin-1 and -2 in node-negative breast cancer: correlation with angiogenic factors, p53, cathepsin D, hormone receptors and prognosis. Oncology (2001) 60(1):72-80.
58. RYDEN L, LINDERHOLM B, NIELSEN NH et al.: Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer. Breast Cancer Res. Treat. (2003) 82(3):147-154.
59. ZONDOR SD, MEDINA PJ: Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann. Pharmacother. (2004) 38(7-8):1258-1264.
60. GORDON MS, MARGOLIN K, TALPAZ M et al.: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. (2001) 19(3):843-850.
61. COBLEIGH MA, LANGMUIR VK, SLEDGE GW et al.: A Phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol (2003) 30(5 Suppl. 16):117-124.
62. MILLER KD, CHAP LI, HOLMES FA et al.: Randomized Phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol. (2005) 23(4):792-799.
63. MILLER KD, WANG M, GRALOW J et al.: A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). SABCS (2005):abstract 3.
64. SAKAMOTO KM: Su-11248 Sugen. Curr. Opin. Investig. Drugs (2004) 5(12):1329-1339.
65. MILLER K, BURNSTEIN H, ELIAS A et al.: Phase II study of SU-11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol. (2005):abstract 563.
66. ABRAMS TJ, LEE LB, MURRAY LJ, PRYER NK, CHERRINGTON JM: SU-11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol. Cancer Ther. (2003) 2(5):471-478.
67. O'FARRELL AM, ABRAMS TJ, YUEN HA et al.: SU-11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood (2003) 101(9):3597-3605.
68. FAIVRE S, DELBALDO C, VERA K et al.: Safety, pharmacokinetic, and antitumor activity of SU-11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol. (2006) 24(1):25-35.
69. SPICER J: Technology evaluation: pertuzumab, Roche/Genentech/Chugai. Curr. Opin. Mol. Ther. (2004) 6(3):337-343.
70. NAHTA R, HUNG MC, ESTEVA FJ: The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. (2004) 64(7):2343-2346.
71. AGUS DB, GORDON MS, TAYLOR C et al.: Phase I clinical study of pertuzumab, a novel her dimerization inhibitor, in patients with advanced cancer. J. Clin. Oncol. (2005) 23(11):2534-2543.
72. CORTES J, BASELGA J, KELLOKUMPU-LEHTINEN P et al.: Open label, randomized, Phase II study of pertuzumab (P) in patients (pts) with metastatic breast cancer (MBC) with low expression of HER2. Proc. Am. Soc. Clin. Oncol. (2005):abstract 3068.
73. XIA W, MULLIN RJ, KEITH BR et al.: Anti-tumor activity of GW-572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene (2002) 21(41):6255-6263.
74. CHU I, BLACKWELL K, CHEN S, SLINGERLAND J: The dual ErbB1/ErbB2 inhibitor, lapatinib (GW-572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. (2005) 65(1):18-25.
75. SPECTOR NL, LIU L, GERARD C et al.: Combining lapatinib (GW-572016) with anti-erbB2 antibodies elicits synergistic apoptotic effects in erbB2 overexpressing breast cancer cells. Proc. Am. Soc. Clin. Oncol. (2005):abstract 557.
76. GOMEZ H, CHAVEZ MA, DOVAL DC et al.: Biomarker results from a Phase II randomized study of lapatinib (GW-572016) as first-line treatment for paitnes with ErbB2-amplified advanced or metastatic breast cancer. San Antonio Breast Cancer Symposium 2005. San Antonio, TX, USA (2005) abstract 1071.
77. VERSOLA M, BURRIS HA 3rd, JONES S et al.: Clinical activity of GW-572016 in EGF-1003 in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. (2004): abstract 3047.
78. BURRIS HA 3rd, HURWITZ HI, DEES EC et al.: Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (gw572016), a reversible, dual inhibitor of epidermal growth factor receptor tyrosine kinases in heavily pretreated patients with metastatic carcinomas. J. Clin. Oncol. (2005) 23(23):5305-5313.
79. SPECTOR NL, XIA W, BURRIS HA 3rd et al.: Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J. Clin. Oncol. 2300:2502-2512.
80. JONES SF, HAINSWORTH JD, SPIGEL DR et al.: A Phase I study of the dual kinase inhibitor GW-572016 in combination with paclitaxel (EGF-10009). Proc. Am. Soc. Clin. Oncol. (2004): abstract 2083.
81. STORNIOLO A, BURRIS HA 3rd, PEGRAM MD et al.: A Phase I, open-label study of lapatinib (GW-572016) plus trastuzumab; a clinically active regimen. Proc. Am. Soc. Clin. Oncol. (2005): abstract 559.
82. CHU Q, GOLDSTEIN LJ, MURRAY N et al.: A Phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW-572016) in combination with letrozole in cancer patients. Proc. Am. Soc. Clin. Oncol. (2005):abstract 3001.
83. BLACKWELL KL, KAPLAN EH, FRANCO SX et al.: A Phase II, open-label, multi-center study of GW-572016 in patients with trastuzumab-refractory metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. (2005):abstract 3006.
84. GOMEZ HL, CHAVEZ MA, DOVAL DC et al.: A Phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH-positive advanced or metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. (2005):abstract 3046.
85. SMITH DA, BOWEN C, HERENDEEN JM et al.: An open-label, randomized, two-way crossover study to evaluate the potential inhibition of GW-572016 metabolism by ketoconazole. Proc. Am. Soc. Clin. Oncol. (2004): abstract 3071.
86. HERENDEEN JM, SMITH DA, STEAD A et al.: An open-label, fixed sequence, two period study to evaluate the potential induction of GW-572016 metabolism by carbamazepine. Proc. Am. Soc. Clin. Oncol. (2004):abstract 3081.
87. SAINSBURY JR, FARNDON JR, NEEDHAM GK, MALCOLM AJ, HARRIS AL: Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet (1987) 1(8547):1398-1402.
88. ROSKOSKI R Jr: The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem. Biophys. Res. Commun. (2004) 319(1):1-11.
89. BASELGA J, ALBANELL J, RUIZ A et al.: Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J. Clin. Oncol. (2005) 23(23):5323-5333.
90. VON MINCKWITZ G, JONAT W, FASCHING P et al.: A multicentre Phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer. Breast Cancer Res. Treat. (2005) 89(2):165-172.
91. PANWALKAR A, VERSTOVSEK S, GILES FJ: Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer (2004) 100(4):657-666.
92. BOULAY A, RUDLOFF J, YE J et al.: Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin. Cancer Res. (2005) 11(14):5319-5328.
93. KOVARIK JM, KAHAN BD, KAPLAN B et al.: Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin. Pharmacol. Ther. (2001) 69(1):48-56.
94. RAYMOND E, ALEXANDRE J, FAIVRE S et al.: Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J. Clin. Oncol. (2004) 22(12):2336-2347.
95. CHAN S, SCHEULEN ME, JOHNSTON S et al.: Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR in heavily pretreated patients with locally advanced or metastatic breast cancer. J. Clin. Oncol. (2005) 23(23):5314-5322.
96. BASSO AD, MIRZA A, LIU G et al.: The farnesyl transferee inhibitor (FTI) SCH-6336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity. J. Biol. Chem. (2005) 280(35):31101-31108.
97. MARCUS AI, ZHOU J, O'BRATE A et al.: The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase. Cancer Res. (2005) 65(9):3883-3893.
98. ELLIS CA, VOS MD, WICKLINE M et al.: Tamoxifen and the farnesyl transferase inhibitor FTI-277 synergize to inhibit growth in estrogen receptor-positive breast tumor cell lines. Breast Cancer Res. Treat. (2003) 78(1):59-67.
99. CRUL M, DE KLERK GJ, SWART M et al.: Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R-115777 in advanced cancer. J. Clin. Oncol. (2002) 20(11):2726-2735.
100. LEBOWITZ PF, ENG-WONG J, WIDEMANN BC et al.: A Phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer. Clin. Cancer Res. (2005) 11(3):1247-1252.
101. JOHNSTON SR, HICKISH T, ELLIS P et al.: Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R-115777, in advanced breast cancer. J. Clin. Oncol. (2003) 21(13):2492-2499.
102. HENNESSY BT, SMITH DL, RAM PT, LU Y, MILLS GB: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. (2005) 4(12):988-1004.
103. EFFERTH T, VOLM M: Pharmacogenetics for individualized cancer chemotherapy. Pharmacol. Ther. (2005) 107(2):155-176.